Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories View More Recent Stories
-
Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength
-
Alcon Reports First Quarter 2020 Results
-
Alcon Reports First Quarter 2020 Results
-
Alcon Provides Update on COVID-19
-
Alcon Provides Update on COVID-19
-
Alcon Showcases Contact Lens, Eye Allergy and Dry Eye Innovations as Title Sponsor of #SECO2020
-
Alcon Showcases Contact Lens, Eye Allergy and Dry Eye Innovations as Title Sponsor of #SECO2020
-
Alcon Reports Full Year 2019 Results
-
Alcon Reports Full Year 2019 Results
-
Alcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch
-
Alcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch
-
Alcon Reports Third Quarter and Nine Months 2019 Results
-
Alcon Reports Third Quarter and Nine Months 2019 Results
-
Alcon Contact Lens and Cataract Innovations to Headline Clinical and Educational Program at #Academy19
-
Alcon Contact Lens and Cataract Innovations to Headline Clinical and Educational Program at #Academy19
-
Alcon to Highlight AcrySof IQ PanOptix Trifocal IOL Launch and Groundbreaking IOL Data at American Academy of Ophthalmology Annual Meeting
-
Alcon to Highlight AcrySof IQ PanOptix Trifocal IOL Launch and Groundbreaking IOL Data at American Academy of Ophthalmology Annual Meeting
-
Alcon Reports Second Quarter and First Half 2019 Results
-
Alcon Reports Second Quarter and First Half 2019 Results
-
Alcon to Launch PRECISION1 Daily Disposable Contact Lenses as it Continues to Deliver on Vision Care Pipeline
-
Alcon to Launch PRECISION1 Daily Disposable Contact Lenses as it Continues to Deliver on Vision Care Pipeline
-
New Alcon DAILIES® COLORS Contact Lenses Give Beauty Lovers Permission to Play with Their Eye Color Every Day
-
Alcon Takes Center Stage with Contact Lens Innovations and the iLUX® System at the 2019 Optometry’s Meeting
-
Gymnast Laurie Hernandez and Alcon Help People See Their Potential with New “Eye Can, Eye Will” Campaign
-
Alcon Reports First Quarter 2019 Trading Update
-
Alcon Reports First Quarter 2019 Trading Update
-
Alcon to Showcase New Clinical Data, Innovative Technology at American Society of Cataract and Refractive Surgery 2019 Annual Meeting
-
Alcon to Showcase New Clinical Data, Innovative Technology at American Society of Cataract and Refractive Surgery 2019 Annual Meeting
-
Berenberg Starts Alcon Inc. (ALC) at Hold
-
Alcon (ALC) to Debut on NYSE Following Novartis Spin-Off
-
Alcon Debuts as Independent, Publicly Traded Company
-
Alcon Debuts as Independent, Publicly Traded Company
-
Cleveland Research Starts Alcon Inc. (ALC) at Neutral
